

Early Clinical PET Imaging Results with the Novel PHF-

Journal of Alzheimer's Disease

34, 457-468

DOI: 10.3233/jad-122059

Citation Report

#	ARTICLE	IF	CITATIONS
1	Neuroimaging in frontotemporal dementia. <i>International Review of Psychiatry</i> , 2013, 25, 221-229.	1.4	70
2	Chronic Traumatic Encephalopathy: <i>Where Are We and Where Are We Going?</i> . <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 407.	2.0	102
3	Biomarker Modeling of Alzheimer's Disease. <i>Neuron</i> , 2013, 80, 1347-1358.	3.8	773
4	Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls. <i>Neuron</i> , 2013, 79, 1094-1108.	3.8	673
5	Functional Connectivity in Alzheimer's Disease: Measurement and Meaning. <i>Biological Psychiatry</i> , 2013, 74, 318-319.	0.7	8
6	Balancing Survival: The Role of CTGF in Controlling Experience-Modulated Olfactory Circuitry. <i>Neuron</i> , 2013, 79, 1037-1039.	3.8	3
7	Imaging Tau Deposits In Vivo: Progress in Viewing More of The Proteopathy Picture. <i>Neuron</i> , 2013, 79, 1035-1037.	3.8	13
8	Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. <i>Nature Reviews Neurology</i> , 2013, 9, 192-200.	4.9	240
9	Tau pathology and neurodegeneration. <i>Lancet Neurology</i> , The, 2013, 12, 609-622.	4.9	893
10	[¹¹ C]PBB3 a new PET ligand that identifies tau pathology in the brains of patients with AD. <i>Nature Reviews Neurology</i> , 2013, 9, 599-599.	4.9	33
11	Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11606-11611.	3.3	105
12	Executive Function Changes before Memory in Preclinical Alzheimer's Pathology: A Prospective, Cross-Sectional, Case Control Study. <i>PLoS ONE</i> , 2013, 8, e79378.	1.1	76
13	A concise radiosynthesis of the tau radiopharmaceutical, [¹⁸ F]T807. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 736-740.	0.5	70
14	Interview: Understanding schizophrenia and traumatic brain injury with MRI. <i>Imaging in Medicine</i> , 2013, 5, 111-118.	0.0	0
15	PET Imaging of Neuropathology in Tauopathies: Progressive Supranuclear Palsy. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 145-153.	1.2	97
16	Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography. , 2014, 04, .		17
17	Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. <i>Disease-Modifying Drugs. Update 2014. Journal of Alzheimer's Disease</i> , 2014, 42, 1079-1149.	1.2	5
19	Antibody-Derived In Vivo Imaging of Tau Pathology. <i>Journal of Neuroscience</i> , 2014, 34, 16835-16850.	1.7	62

#	ARTICLE	IF	CITATIONS
20	Biomarkers in frontotemporal dementia. <i>Biomarkers in Medicine</i> , 2014, 8, 519-521.	0.6	5
21	Tracking the earliest pathologic changes in Alzheimer disease. <i>Neurology</i> , 2014, 82, 1576-1577.	1.5	19
22	New tools for the evaluation of patients with neurodegenerative diseases. <i>Neurodegenerative Disease Management</i> , 2014, 4, 403-405.	1.2	0
23	Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives. <i>Future Neurology</i> , 2014, 9, 597-613.	0.9	3
24	Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 323-331.	0.5	39
25	Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 925-929.	0.9	135
26	Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 18-24.	0.5	31
27	Tau PET Imaging in Alzheimer's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 500.	2.0	141
28	Positron Emission Tomography Molecular Imaging in Late-Life Depression. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014, 27, 13-23.	1.2	10
29	PART and SNAP. <i>Acta Neuropathologica</i> , 2014, 128, 773-776.	3.9	78
30	Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 51.	3.0	24
31	Multimodality Imaging of Alzheimer Disease and Other Neurodegenerative Dementias. <i>Journal of Nuclear Medicine</i> , 2014, 55, 2003-2011.	2.8	54
32	FDG-PET and amyloid-PET imaging. <i>Current Opinion in Neurology</i> , 2014, 27, 405-413.	1.8	55
33	Developments in Tau PET Imaging. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, 547-553.	0.3	45
34	Tau Immunotherapy and Imaging. <i>Neurodegenerative Diseases</i> , 2014, 13, 103-106.	0.8	23
35	In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals. <i>Translational Neurodegeneration</i> , 2014, 3, 6.	3.6	27
36	Update on SPECT and PET in parkinsonism – part 2. <i>Current Opinion in Neurology</i> , 2014, 27, 398-404.	1.8	14
37	The neuropathology of sport. <i>Acta Neuropathologica</i> , 2014, 127, 29-51.	3.9	348

#	ARTICLE	IF	CITATIONS
38	Biomarker Modelling of Early Molecular Changes in Alzheimer's Disease. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 213-227.	1.6	4
39	Concise and high-yield synthesis of T808 and T808P for radiosynthesis of [18F]-T808, a PET tau tracer for Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 254-257.	1.0	24
40	Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. <i>Brain</i> , 2014, 137, 1762-1771.	3.7	234
41	Synthesis of a new fluorine-18-labeled bexarotene analogue for PET imaging of retinoid X receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1742-1747.	1.0	5
42	Alzheimer's disease and other dementias: advances in 2013. <i>Lancet Neurology</i> , The, 2014, 13, 3-5.	4.9	29
43	Time for tau. <i>Brain</i> , 2014, 137, 1570-1571.	3.7	11
44	Neuroimaging the Epileptogenic Process. <i>Neurotherapeutics</i> , 2014, 11, 347-357.	2.1	37
45	The Evolution of Preclinical Alzheimer's Disease: Implications for Prevention Trials. <i>Neuron</i> , 2014, 84, 608-622.	3.8	568
46	MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. <i>Trends in Neurosciences</i> , 2014, 37, 629-641.	4.2	38
47	Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers. <i>Journal of Nuclear Medicine</i> , 2014, 55, 871-874.	2.8	66
48	Mild Cognitive Impairment and Mild Dementia: A Clinical Perspective. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1452-1459.	1.4	227
49	Imaging Frontotemporal Lobar Degeneration. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 489.	2.0	41
50	Structural Imaging Measures of Brain Aging. <i>Neuropsychology Review</i> , 2014, 24, 271-289.	2.5	199
51	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 1.	3.0	156
52	Neuroimaging in repetitive brain trauma. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 10.	3.0	49
53	Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of ¹¹ C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1532-1538.	2.8	125
54	In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 816-826.	3.3	156
55	Current Understanding of Chronic Traumatic Encephalopathy. <i>Current Treatment Options in Neurology</i> , 2014, 16, 306.	0.7	74

#	ARTICLE	IF	CITATIONS
56	Imaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 472.	2.0	33
57	Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. <i>Lancet, The</i> , 2014, 384, 532-544.	6.3	129
58	Network Dysfunction in Alzheimer's Disease: Refining the Disconnection Hypothesis. <i>Brain Connectivity</i> , 2014, 4, 299-311.	0.8	151
59	High Affinity Radiopharmaceuticals Based Upon Lansoprazole for PET Imaging of Aggregated Tau in Alzheimer's Disease and Progressive Supranuclear Palsy: Synthesis, Preclinical Evaluation, and Lead Selection. <i>ACS Chemical Neuroscience</i> , 2014, 5, 718-730.	1.7	77
60	Cognition in corticobasal syndrome and progressive supranuclear palsy: A review. <i>Movement Disorders</i> , 2014, 29, 684-693.	2.2	137
61	In vivo tau imaging: Obstacles and progress. , 2014, 10, S254-S264.		84
62	Cognitive changes and dementia risk after traumatic brain injury: Implications for aging military personnel. <i>Alzheimer's and Dementia</i> , 2014, 10, S174-87.	0.4	63
66	Spreading of Amyloid, Tau, and Microvascular Pathology in Alzheimer's Disease: Findings from Neuropathological and Neuroimaging Studies. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S421-S429.	1.2	75
67	Harnessing the Immune System for Treatment and Detection of Tau Pathology. <i>Journal of Alzheimer's Disease</i> , 2014, 40, S113-S121.	1.2	18
68	First Human Use of a Radiopharmaceutical Prepared by Continuous-Flow Microfluidic Radiofluorination: Proof of Concept with the Tau Imaging Agent [¹⁸ F]T807. <i>Molecular Imaging</i> , 2014, 13, 7290.2014.00025.	0.7	32
69	The Pattern of Brain Amyloid Load in Posterior Cortical Atrophy Using 18F-AV45: Is Amyloid the Principal Actor in the Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 431-441.	0.6	10
70	Rates of β -amyloid accumulation are independent of hippocampal neurodegeneration. <i>Neurology</i> , 2014, 82, 1605-1612.	1.5	119
73	Abnormalities of plasma cytokines and spleen in senile APP/PS1/Tau transgenic mouse model. <i>Scientific Reports</i> , 2015, 5, 15703.	1.6	27
74	Dementia with Lewy bodies can be well differentiated from Alzheimer's disease by measurement of brain acetylcholinesterase activity—a [¹¹ C]MP4A PET study. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 1105-1113.	1.3	30
75	A Review of Neuroimaging Findings in Repetitive Brain Trauma. <i>Brain Pathology</i> , 2015, 25, 318-349.	2.1	107
76	Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. <i>Annals of Neurology</i> , 2015, 77, 338-342.	2.8	124
77	Validating novel tau positron emission tomography tracer [¹⁸ F]AV-451 (T807) on postmortem brain tissue. <i>Annals of Neurology</i> , 2015, 78, 787-800.	2.8	535
78	The Neuropathology of Chronic Traumatic Encephalopathy. <i>Brain Pathology</i> , 2015, 25, 350-364.	2.1	411

#	ARTICLE	IF	CITATIONS
79	Optimizing Central Nervous System Drug Development Using Molecular Imaging. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 47-60.	2.3	28
80	Imaging pathological tau in atypical parkinsonian disorders. <i>Current Opinion in Neurology</i> , 2015, 28, 447-452.	1.8	5
81	PET Imaging of Tau Pathology in Alzheimer's Disease and Tauopathies. <i>Frontiers in Neurology</i> , 2015, 6, 38.	1.1	82
82	Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology. <i>Frontiers in Neurology</i> , 2015, 6, 236.	1.1	102
83	Neuroimaging assessment of early and late neurobiological sequelae of traumatic brain injury: implications for CTE. <i>Frontiers in Neuroscience</i> , 2015, 9, 334.	1.4	35
84	Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging. <i>Frontiers in Neuroscience</i> , 2015, 9, 482.	1.4	26
85	Longitudinal Assessment of Tau Pathology in Patients with Alzheimer's Disease Using [18F]THK-5117 Positron Emission Tomography. <i>PLoS ONE</i> , 2015, 10, e0140311.	1.1	75
86	Novel PET/SPECT Probes for Imaging of Tau in Alzheimer's Disease. <i>Scientific World Journal</i> , The, 2015, 2015, 1-6.	0.8	17
87	Fully automated synthesis of [18F]T807, a PET tau tracer for Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2953-2957.	1.0	24
88	Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. <i>Human Brain Mapping</i> , 2015, 36, 4421-4437.	1.9	196
89	Massachusetts Alzheimer's Disease Research Center: Progress and challenges. <i>Alzheimer's and Dementia</i> , 2015, 11, 1241-1245.	0.4	7
90	Chronic Traumatic Encephalopathy: Historical Origins and Current Perspective. <i>Annual Review of Clinical Psychology</i> , 2015, 11, 309-330.	6.3	92
91	Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4365-4382.	2.9	88
92	Spreading of pathology in neurodegenerative diseases: a focus on human studies. <i>Nature Reviews Neuroscience</i> , 2015, 16, 109-120.	4.9	611
93	Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (<i>MAPT</i>) mutations: a chameleon for neuropathology and neuroimaging. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 24-46.	1.8	360
94	The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. <i>Alzheimer's and Dementia</i> , 2015, 11, 1.	0.4	603
95	Key emerging issues in progressive supranuclear palsy and corticobasal degeneration. <i>Journal of Neurology</i> , 2015, 262, 783-788.	1.8	21
96	The neuropathology of traumatic brain injury. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2015, 127, 45-66.	1.0	479

#	ARTICLE	IF	CITATIONS
98	Understanding Biomarkers of Neurodegeneration: Novel approaches to detecting tau pathology. <i>Nature Medicine</i> , 2015, 21, 219-220.	15.2	15
99	Chronic Traumatic Encephalopathy: A Neurodegenerative Consequence of Repetitive Traumatic Brain Injury. <i>Seminars in Neurology</i> , 2015, 35, 020-028.	0.5	33
100	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. <i>Alzheimer's and Dementia</i> , 2015, 11, 865-884.	0.4	181
101	Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease. <i>Neurobiology of Aging</i> , 2015, 36, 2483-2500.	1.5	108
102	Facile Route to 2-Fluoropyridines via 2-Pyridyltrialkylammonium Salts Prepared from Pyridine <i>N</i> -Oxides and Application to ¹⁸ F-Labeling. <i>Organic Letters</i> , 2015, 17, 3726-3729.	2.4	53
103	The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. <i>Alzheimer's and Dementia</i> , 2015, 11, 757-771.	0.4	199
104	A Review of the Effectiveness of Neuroimaging Modalities for the Detection of Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2015, 32, 1693-1721.	1.7	163
105	Ice Hockey Summit II: Zero Tolerance for Head Hits and Fighting. <i>PM and R</i> , 2015, 7, 283-295.	0.9	6
107	The role of positron emission tomography imaging in understanding Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 395-406.	1.4	27
108	[¹⁸ F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1052-1061.	3.3	117
109	Neuroimaging and traumatic brain injury: State of the field and voids in translational knowledge. <i>Molecular and Cellular Neurosciences</i> , 2015, 66, 103-113.	1.0	22
110	Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 110-118.	1.3	96
111	The Neuropsychiatric Examination of the Young-Onset Dementias. <i>Psychiatric Clinics of North America</i> , 2015, 38, 249-264.	0.7	28
112	Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use. <i>CNS Drugs</i> , 2015, 29, 313-330.	2.7	14
113	Ice Hockey Summit II. <i>Clinical Journal of Sport Medicine</i> , 2015, 25, 78-87.	0.9	8
114	Case 9-2015. <i>New England Journal of Medicine</i> , 2015, 372, 1151-1162.	13.9	9
116	Chronic traumatic encephalopathy: Contributions from the Boston University Center for the Study of Traumatic Encephalopathy. <i>Brain Injury</i> , 2015, 29, 154-163.	0.6	27
117	Tau immunotherapy for Alzheimer's disease. <i>Trends in Molecular Medicine</i> , 2015, 21, 394-402.	3.5	224

#	ARTICLE	IF	CITATIONS
118	Synthesis of a PET tau tracer [11C]PBB3 for imaging of Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4587-4592.	1.0	28
119	Quantitative imaging of protein targets in the human brain with PET. <i>Physics in Medicine and Biology</i> , 2015, 60, R363-R411.	1.6	61
120	Identification of a major radiometabolite of [11C]PBB3. <i>Nuclear Medicine and Biology</i> , 2015, 42, 905-910.	0.3	37
121	Structure-Activity Relationship Study of Heterocyclic Phenylethenyl and Pyridinylethenyl Derivatives as Tau-Imaging Agents That Selectively Detect Neurofibrillary Tangles in Alzheimer's Disease Brains. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7241-7257.	2.9	41
122	PET Radioligands for Imaging of Tau Pathology: Current Status. <i>Nuclear Medicine and Molecular Imaging</i> , 2015, 49, 251-257.	0.6	9
123	Relationships between default-mode network connectivity, medial temporal lobe structure, and age-related memory deficits. <i>Neurobiology of Aging</i> , 2015, 36, 265-272.	1.5	86
124	Tau imaging: early progress and future directions. <i>Lancet Neurology</i> , The, 2015, 14, 114-124.	4.9	432
125	Invited review: Drug development for tauopathies. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 81-96.	1.8	31
126	Imaging of Alzheimer's disease: Part 1. , 2016, , .		0
127	Imaging Alzheimer's disease pathophysiology with PET. <i>Dementia E Neuropsychologia</i> , 2016, 10, 79-90.	0.3	33
128	Financial Decision-Making and Capacity in Older Adults. , 2016, , 361-388.		6
129	Insight into the Molecular Imaging of Alzheimer's Disease. <i>International Journal of Biomedical Imaging</i> , 2016, 2016, 1-17.	3.0	16
130	Characteristics of Tau and Its Ligands in PET Imaging. <i>Biomolecules</i> , 2016, 6, 7.	1.8	86
131	Optimization and Biodistribution of [11C]-TKF, An Analog of Tau Protein Imaging Agent [18F]-THK523. <i>Molecules</i> , 2016, 21, 1019.	1.7	3
132	Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351. <i>PLoS ONE</i> , 2016, 11, e0158460.	1.1	85
133	Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT. <i>Frontiers in Pharmacology</i> , 2016, 7, 88.	1.6	22
134	Tau PET Imaging for Dementia in Clinical Practice. <i>Radioisotopes</i> , 2016, 65, 517-522.	0.1	0
135	¹⁸ F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. <i>Brain</i> , 2016, 139, 2372-2379.	3.7	149

#	ARTICLE	IF	CITATIONS
137	Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 339-343.	1.2	30
138	Tau in Late-Life Depression: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 615-633.	1.2	23
139	Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 927-945.	1.2	22
141	Imaging of frontotemporal dementia. , 0, , 125-142.		0
142	Comparison of New Tau PET-Tracer Candidates With [¹⁸ F]T808 and [¹⁸ F]T807. <i>Molecular Imaging</i> , 2016, 15, 153601211562492.	0.7	37
143	PET Imaging of Tau Deposition in the Aging Human Brain. <i>Neuron</i> , 2016, 89, 971-982.	3.8	899
144	Molecular and cellular pathophysiology of preclinical Alzheimer's disease. <i>Behavioural Brain Research</i> , 2016, 311, 54-69.	1.2	99
145	Tau: From research to clinical development. <i>Alzheimer's and Dementia</i> , 2016, 12, 1033-1039.	0.4	117
146	Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review. <i>BMC Geriatrics</i> , 2016, 16, 104.	1.1	59
147	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. <i>Alzheimer's and Dementia</i> , 2016, 12, 510-515.	0.4	23
148	<i>In vivo</i> imaging of neurodegeneration in dementia with Lewy bodies (DLB). <i>International Psychogeriatrics</i> , 2016, 28, 527-528.	0.6	1
149	Regional profiles of the candidate tau PET ligand [¹⁸ F]-AV-1451 recapitulate key features of Braak histopathological stages. <i>Brain</i> , 2016, 139, 1539-1550.	3.7	372
150	Nuclear Imaging of Dementia. , 2016, , 233-240.		0
152	Discovery of 6-(Fluoro- ¹⁸ F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([¹⁸ F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4778-4789.	2.9	142
153	Human Radiation Dosimetry of [¹⁸ F]AV-1451(T807) to Detect Tau Pathology. <i>Molecular Imaging and Biology</i> , 2016, 18, 479-482.	1.3	13
154	Cerebral [¹⁸ F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy. <i>Translational Psychiatry</i> , 2016, 6, e900-e900.	2.4	63
155	Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. <i>JAMA Neurology</i> , 2016, 73, 1334.	4.5	182
156	Untangling tau imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 39-42.	1.2	4

#	ARTICLE	IF	CITATIONS
157	Advances in neuroimaging in frontotemporal dementia. <i>Journal of Neurochemistry</i> , 2016, 138, 193-210.	2.1	75
158	Tau positron emission tomographic imaging in aging and early Alzheimer disease. <i>Annals of Neurology</i> , 2016, 79, 110-119.	2.8	778
159	A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2244-2254.	3.3	37
160	Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. <i>JAMA Neurology</i> , 2016, 73, 1185.	4.5	52
161	The amyloid hypothesis of Alzheimer's disease at 25 years. <i>EMBO Molecular Medicine</i> , 2016, 8, 595-608.	3.3	4,226
162	Neuroimaging Biomarkers in Alzheimer's Disease. , 2016, , 51-100.		8
163	An autoradiographic evaluation of AV-1451 Tau PET in dementia. <i>Acta Neuropathologica Communications</i> , 2016, 4, 58.	2.4	388
164	Repetitive Head Impacts and Chronic Traumatic Encephalopathy. <i>Neurosurgery Clinics of North America</i> , 2016, 27, 529-535.	0.8	114
165	[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. <i>Acta Neuropathologica</i> , 2016, 132, 931-933.	3.9	116
166	Tau and tauopathies. <i>Brain Research Bulletin</i> , 2016, 126, 238-292.	1.4	444
167	Tau PET in Alzheimer disease and mild cognitive impairment. <i>Neurology</i> , 2016, 87, 375-383.	1.5	208
168	Genetic and degenerative disorders primarily causing dementia. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016, 135, 525-564.	1.0	5
169	Neuroimaging Advances in Alzheimer's Disease. , 2016, , 263-282.		1
170	Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β -Amyloid and Tauopathy. <i>JAMA Neurology</i> , 2016, 73, 1070.	4.5	246
171	Tau and β imaging, CSF measures, and cognition in Alzheimer's disease. <i>Science Translational Medicine</i> , 2016, 8, 338ra66.	5.8	560
172	Highly Selective Tau-SPECT Imaging Probes for Detection of Neurofibrillary Tangles in Alzheimer's Disease. <i>Scientific Reports</i> , 2016, 6, 34197.	1.6	25
173	In vivo visualization of tau deposits in corticobasal syndrome by ¹⁸ F-THK5351 PET. <i>Neurology</i> , 2016, 87, 2309-2316.	1.5	105
174	Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2211-2218.	3.3	18

#	ARTICLE	IF	CITATIONS
175	Late-onset neurocognitive deficits following traumatic brain injury: chronic traumatic encephalopathy (CTE) and psychotic disorder following TBI (PDF TBI). Higher Brain Function Research, 2016, 35, 276-282.	0.0	2
176	Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. EMBO Reports, 2016, 17, 530-551.	2.0	103
177	PET Imaging as a Diagnostic Tool in Alzheimer's Disease. Methods in Pharmacology and Toxicology, 2016, , 199-213.	0.1	0
178	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain, 2016, 139, 2249-2260.	3.7	150
179	The incubation period of Alzheimer's disease and the timing of tau versus amyloid misfolding and spreading within the brain. European Journal of Epidemiology, 2016, 31, 99-105.	2.5	11
180	Kinetics of the Tau PET Tracer ¹⁸ F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease. Journal of Nuclear Medicine, 2016, 57, 1535-1542.	2.8	84
181	The Complex Pathways to Mechanism-Based Therapeutics in Alzheimer's Disease. , 2016, , 1-22.		0
182	Inhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer's Disease. , 2016, , 385-436.		1
183	Prospects and Challenges for Alzheimer Therapeutics. , 2016, , 605-637.		2
184	Tau PET: the next frontier in molecular imaging of dementia. International Psychogeriatrics, 2016, 28, 1403-1406.	0.6	2
185	Preclinical Characterization of ¹⁸ F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles. Journal of Nuclear Medicine, 2016, 57, 1599-1606.	2.8	216
186	Tracer Kinetic Analysis of ¹⁸ F-THK5117 as a PET Tracer for Assessing Tau Pathology. Journal of Nuclear Medicine, 2016, 57, 574-581.	2.8	51
187	Advances in the development of tau PET radiotracers and their clinical applications. Ageing Research Reviews, 2016, 30, 107-113.	5.0	57
188	Suspected non-Alzheimer disease pathophysiology "concept and controversy. Nature Reviews Neurology, 2016, 12, 117-124.	4.9	230
189	PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies. Neurodegenerative Diseases, 2016, 16, 118-124.	0.8	44
190	Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. Seminars in Nuclear Medicine, 2016, 46, 57-87.	2.5	16
191	Tau and neurodegenerative disease: the story so far. Nature Reviews Neurology, 2016, 12, 15-27.	4.9	603
192	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.4	1,318

#	ARTICLE	IF	CITATIONS
193	Neuroimaging in Alzheimer's disease: preclinical challenges toward clinical efficacy. <i>Translational Research</i> , 2016, 175, 37-53.	2.2	6
194	¹⁸ F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 208-214.	2.8	282
195	Potential Long-Term Consequences of Concussive and Subconcussive Injury. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2016, 27, 503-511.	0.7	61
196	Tau Immunotherapy. <i>Neurodegenerative Diseases</i> , 2016, 16, 34-38.	0.8	53
197	Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. <i>Brain</i> , 2016, 139, 1551-1567.	3.7	833
198	Structure-Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 608-614.	2.8	56
199	Tau imaging in neurodegenerative diseases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1139-1150.	3.3	104
200	Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions. <i>Current Opinion in Neurobiology</i> , 2016, 36, 43-51.	2.0	66
201	Imaging biomarkers in tauopathies. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S26-S28.	1.1	23
202	Preclinical Evaluation of [18F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer. <i>Molecular Imaging and Biology</i> , 2016, 18, 258-266.	1.3	29
203	New protein deposition tracers in the pipeline. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2017, 1, 11.	1.8	15
204	Synthesis of carbon-11-labeled isonicotinamides as new potential PET agents for imaging of GSK-3 enzyme in Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 740-743.	1.0	11
205	Discovery of <i>N</i> -(Pyridin-4-yl)-1,5-naphthyridin-2-amines as Potential Tau Pathology PET Tracers for Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1272-1291.	2.9	31
206	Association between A β 2 and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [¹¹ C]PBB3 PET study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 11-20.	1.2	66
207	Neurologic Applications of PET/MR Imaging. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2017, 25, 297-313.	0.6	36
208	Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	354
209	Frontotemporal dementia with the V337M <i>MAPT</i> mutation. <i>Neurology</i> , 2017, 88, 758-766.	1.5	76
210	Tau PET imaging: present and future directions. <i>Molecular Neurodegeneration</i> , 2017, 12, 19.	4.4	220

#	ARTICLE	IF	CITATIONS
211	Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3150-3160.	2.4	48
212	Preclinical Evaluation of ¹⁸ F-JNJ64349311, a Novel PET Tracer for Tau Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 975-981.	2.8	72
213	Future Directions in Imaging Neurodegeneration. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 9.	2.0	13
214	Association of In Vivo [¹⁸ F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 427.	4.5	236
215	Amyloid and tau PET demonstrate region-specific associations in normal older people. <i>NeuroImage</i> , 2017, 150, 191-199.	2.1	67
216	Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. <i>Annals of Neurology</i> , 2017, 81, 583-596.	2.8	110
217	PET Imaging Agents for Alzheimer's Disease. <i>Topics in Medicinal Chemistry</i> , 2017, , 181-197.	0.4	0
218	Quantification of Tau Load Using [¹⁸ F]AV1451 PET. <i>Molecular Imaging and Biology</i> , 2017, 19, 963-971.	1.3	42
219	The Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly. <i>Neurologic Clinics</i> , 2017, 35, 231-262.	0.8	5
220	Poster Presentations. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 111-640.	0.5	6
221	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , 2017, 32, 955-971.	2.2	179
222	Alzheimer's Disease II. <i>Topics in Medicinal Chemistry</i> , 2017, , .	0.4	2
223	Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias. <i>PET Clinics</i> , 2017, 12, 351-359.	1.5	21
224	Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses. <i>BMJ Open</i> , 2017, 7, e013187.	0.8	65
225	Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to \pm -synuclein pathology. <i>Movement Disorders</i> , 2017, 32, 884-892.	2.2	55
226	Advancing Drug Discovery and Development Using Molecular Imaging (ADDMI): an Interest Group of the World Molecular Imaging Society and an Inaugural Session on Positron Emission Tomography (PET). <i>Molecular Imaging and Biology</i> , 2017, 19, 348-356.	1.3	4
227	A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 637-648.	4.0	164
228	Increased basal ganglia binding of ¹⁸ F- ¹⁸ F-AV-1451 in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 2017, 32, 108-114.	2.2	111

#	ARTICLE	IF	CITATIONS
229	Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease. <i>Brain</i> , 2017, 140, 2002-2011.	3.7	147
230	The association between tau PET and retrospective cortical thinning in clinically normal elderly. <i>NeuroImage</i> , 2017, 157, 612-622.	2.1	74
231	Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex. <i>JAMA Neurology</i> , 2017, 74, 813.	4.5	61
232	[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging. <i>Acta Neuropathologica</i> , 2017, 134, 619-628.	3.9	77
233	Tau and amyloid β proteins distinctively associate to functional network changes in the aging brain. <i>Alzheimer's and Dementia</i> , 2017, 13, 1261-1269.	0.4	90
234	Biodistribution and Radiation Dosimetry for the Tau Tracer ¹⁸ F-THK-5351 in Healthy Human Subjects. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1498-1503.	2.8	21
235	Association between tau deposition and antecedent amyloid- β accumulation rates in normal and early symptomatic individuals. <i>Brain</i> , 2017, 140, 1499-1512.	3.7	93
236	Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 645-665.	1.2	139
237	In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings. <i>Ageing Research Reviews</i> , 2017, 36, 50-63.	5.0	107
238	Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals. <i>Journal of Neuroscience</i> , 2017, 37, 4323-4331.	1.7	237
239	Kinetic Modeling of the Tau PET Tracer ¹⁸ F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1124-1131.	2.8	60
240	Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 21-30.	1.2	86
241	Tau Positron Emission Tomography Imaging. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a023721.	2.3	24
242	Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a024034.	2.9	15
243	Development of a BODIPY-based fluorescent probe for imaging pathological tau aggregates in live cells. <i>Chemical Communications</i> , 2017, 53, 1607-1610.	2.2	43
244	Pathological correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies. <i>Annals of Neurology</i> , 2017, 81, 117-128.	2.8	174
245	Olfactory identification in subjective cognitive decline and mild cognitive impairment: Association with tau but not amyloid positron emission tomography. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 57-66.	1.2	44
246	Uptake of AV-1451 in meningiomas. <i>Annals of Nuclear Medicine</i> , 2017, 31, 736-743.	1.2	7

#	ARTICLE	IF	CITATIONS
247	Radiopharmaceuticals for Assessment of Altered Metabolism and Biometal Fluxes in Brain Aging and Alzheimer's Disease with Positron Emission Tomography. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 527-536.	1.2	2
248	New PET markers for the diagnosis of dementia. <i>Current Opinion in Neurology</i> , 2017, 30, 608-616.	1.8	16
249	The Biological Basis of Chronic Traumatic Encephalopathy following Blast Injury: A Literature Review. <i>Journal of Neurotrauma</i> , 2017, 34, S-26-S-43.	1.7	26
251	Small-molecule PET Tracers for Imaging Proteinopathies. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 553-575.	2.5	91
252	Quinuclidine and DABCO Enhance the Radiofluorination of Substituted Halopyridines. <i>European Journal of Organic Chemistry</i> , 2017, 2017, 6593-6603.	1.2	16
253	A Difluoroboron ¹² -Diketonate Probe Shows Turn-on Near-Infrared Fluorescence Specific for Tau Fibrils. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2124-2131.	1.7	41
254	Clinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 429-453.	2.5	25
255	¹⁸ F-AV1451 and CSF τ and $P\tau$ as biomarkers in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2017, 9, 1212-1223.	3.3	156
256	AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. <i>NeuroImage</i> , 2017, 161, 171-178.	2.1	116
257	Tau-imaging in neurodegeneration. <i>Methods</i> , 2017, 130, 114-123.	1.9	34
258	Emerging Diagnostic and Therapeutic Strategies for Tauopathies. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 72.	2.0	31
259	Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1291-1303.	1.4	50
260	Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 509-513.	1.2	11
261	Neuroimaging in the Diagnosis of Chronic Traumatic Encephalopathy: A Systematic Review. <i>Clinical Journal of Sport Medicine</i> , 2020, 30, S1-S10.	0.9	21
262	Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. <i>Brain</i> , 2017, 140, aww339.	3.7	153
263	Parietal white matter lesions in Alzheimer's disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. <i>Acta Neuropathologica</i> , 2017, 134, 459-473.	3.9	180
264	Biomarkers in Neurodegenerative Diseases. <i>Advances in Neurobiology</i> , 2017, 15, 491-528.	1.3	69
265	Radiosynthesis of [¹⁸ F]AV1451 in pharmaceutical conditions and its biological characteristics. <i>Applied Radiation and Isotopes</i> , 2017, 128, 101-107.	0.7	5

#	ARTICLE	IF	CITATIONS
266	Imaging tau pathology in Parkinsonisms. Npj Parkinson's Disease, 2017, 3, 22.	2.5	13
267	Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimer's Disease with Positron Emission Tomography. Journal of Medicinal Chemistry, 2017, 60, 7350-7370.	2.9	74
268	Tau imaging with [¹⁸ F]THK-5351 in progressive supranuclear palsy. European Journal of Neurology, 2017, 24, 130-136.	1.7	87
269	Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics, 2017, 14, 35-53.	2.1	128
270	A report of the automated radiosynthesis of the tau positron emission tomography radiopharmaceutical, [18F]-THK-5351. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 140-146.	0.5	2
271	Imaging Approaches to Cerebral Cortex Pathology. , 2017, , 57-80.		0
273	Modeling Strategies for Quantification of In Vivo ¹⁸ F-AV-1451 Binding in Patients with Tau Pathology. Journal of Nuclear Medicine, 2017, 58, 623-631.	2.8	53
274	[¹⁸ F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Movement Disorders, 2017, 32, 124-133.	2.2	136
275	Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance. Brain Imaging and Behavior, 2017, 11, 383-390.	1.1	54
276	A β -amyloid and Tau Imaging in Dementia. Seminars in Nuclear Medicine, 2017, 47, 75-88.	2.5	96
277	Pharmacokinetic Evaluation of the Tau PET Radiotracer ¹⁸ F-T807 (¹⁸ F-AV-1451) in Human Subjects. Journal of Nuclear Medicine, 2017, 58, 484-491.	2.8	73
278	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 83-91.	1.8	94
279	Molecular Imaging and Precision Medicine in Dementia and Movement Disorders. PET Clinics, 2017, 12, 119-136.	1.5	1
280	Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials. Neurotherapeutics, 2017, 14, 62-68.	2.1	26
281	¹⁸ F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain, 2017, 140, aww340.	3.7	174
282	Neuroimaging in dementia. , 0, , 19-43.		0
283	The non-fluent/agrammatic variant of primary progressive aphasia. , 0, , 164-177.		0
284	PET Tau and Amyloid- β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2017, 60, 283-293.	1.2	67

#	ARTICLE	IF	CITATIONS
285	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. <i>Brain</i> , 2017, 140, 2286-2294.	3.7	149
286	Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 975-985.	1.2	70
287	The emerging role of PET imaging in dementia. <i>F1000Research</i> , 2017, 6, 1830.	0.8	43
288	Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease. <i>Chinese Medical Journal</i> , 2017, 130, 2978-2990.	0.9	49
290	[18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation. <i>Journal of Neurology</i> , 2018, 265, 1079-1088.	1.8	29
291	A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date. <i>Journal of Neurotrauma</i> , 2018, 35, 2015-2024.	1.7	25
292	Synthesis of carbon-11-labeled 5-HT ₆ R antagonists as new candidate PET radioligands for imaging of Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1836-1841.	1.0	7
293	NIA's Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.	0.4	5,861
294	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1713-1724.	1.2	45
295	Imaging tau and amyloid- β proteinopathies in Alzheimer disease and other conditions. <i>Nature Reviews Neurology</i> , 2018, 14, 225-236.	4.9	321
296	Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models. <i>Journal of Nuclear Medicine</i> , 2018, 59, 960-966.	2.8	68
297	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. <i>Cortex</i> , 2018, 99, 358-374.	1.1	42
298	In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1037-1052.	1.2	60
299	Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 548.	4.5	137
300	Modeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1287-1303.	1.2	30
301	The tau positron emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. <i>Movement Disorders</i> , 2018, 33, 273-281.	2.2	119
302	Associations between [¹⁸ F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. <i>Neurology</i> , 2018, 90, e282-e290.	1.5	113
303	Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18. <i>Journal of Nuclear Medicine</i> , 2018, 59, 937-943.	2.8	55

#	ARTICLE	IF	CITATIONS
304	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 3-9.	1.1	27
305	Comparing ¹⁸ F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , 2018, 90, e388-e395.	1.5	83
306	[¹⁸ F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 83, 248-257.	2.8	67
307	Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia. <i>Brain</i> , 2018, 141, 288-301.	3.7	56
308	Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy. <i>Brain</i> , 2018, 141, 550-567.	3.7	190
309	Imaging β 2 and tau in early stage Alzheimer's disease with [¹⁸ F]AV45 and [¹⁸ F]AV1451. <i>EJNMMI Research</i> , 2018, 8, 19.	1.1	14
310	Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β 2 positron emission tomography pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 245-252.	1.2	49
311	2018 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2018, 14, 367-429.	0.4	1,522
312	Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 24-30.	0.6	13
313	¹⁸ F-Flortaucipir PET/MRI Correlations in Nonamnesic and Amnesic Variants of Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2018, 59, 299-306.	2.8	48
314	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215
315	Preclinical Evaluation of ¹⁸ F-RO6958948, ¹¹ C-RO6931643, and ¹¹ C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2018, 59, 675-681.	2.8	71
316	[¹⁸ F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 62-69.	0.6	32
317	Selective Tau Imaging: <i>Der Stand der Dinge</i> . <i>Journal of Nuclear Medicine</i> , 2018, 59, 175-176.	2.8	17
318	[¹⁸ F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1032-1037.	0.9	77
319	Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. <i>Human Brain Mapping</i> , 2018, 39, 691-708.	1.9	59
320	Head to head comparison of [¹⁸ F] AV-1451 and [¹⁸ F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 432-442.	3.3	51
323	6 .Diagnostische Methoden. , 2018, , 187-352.		0

#	ARTICLE	IF	CITATIONS
324	The impact of amyloid β and tau on prospective cognitive decline in older individuals. <i>Annals of Neurology</i> , 2019, 85, 181-193.	2.8	171
325	Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. <i>Nature Medicine</i> , 2018, 24, 1910-1918.	15.2	135
326	Detection of tau in Gerstmann-Str \ddot{a} ussler-Scheinker disease (PRNP F198S) by [18 F]Flortaucipir PET. <i>Acta Neuropathologica Communications</i> , 2018, 6, 114.	2.4	10
327	Widespread distribution of tauopathy in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 72, 177-185.	1.5	42
328	A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer's Disease. <i>Brain Sciences</i> , 2018, 8, 162.	1.1	8
329	Disease-related patterns of in vivo pathology in Corticobasal syndrome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2413-2425.	3.3	26
330	Focused Ultrasound-Induced Blood-Brain Barrier Opening Enhances GSK-3 Inhibitor Delivery for Amyloid-Beta Plaque Reduction. <i>Scientific Reports</i> , 2018, 8, 12882.	1.6	48
332	Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S633-S646.	1.2	52
333	Synthesis of carbon-11-labeled CK1 inhibitors as new potential PET radiotracers for imaging of Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2234-2238.	1.0	5
334	Alpha Synuclein Fibrils Contain Multiple Binding Sites for Small Molecules. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2521-2527.	1.7	48
335	PET/CT of Dementia. <i>American Journal of Roentgenology</i> , 2018, 211, 246-259.	1.0	18
336	In vivo quantification of neurofibrillary tangles with [18 F]MK-6240. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 74.	3.0	120
337	Neuroimaging-pathological correlations of [18 F]THK5351 PET in progressive supranuclear palsy. <i>Acta Neuropathologica Communications</i> , 2018, 6, 53.	2.4	54
338	From simultaneous to synergistic MR \rightarrow PET brain imaging: A review of hybrid MR \rightarrow PET imaging methodologies. <i>Human Brain Mapping</i> , 2018, 39, 5126-5144.	1.9	62
339	Role of Neuroimaging as a Biomarker for Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2018, 9, 265.	1.1	32
340	An Algorithm for Preclinical Diagnosis of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 275.	1.4	38
341	Distinct [18 F]THK5351 binding patterns in primary progressive aphasia variants. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2342-2357.	3.3	16
342	Molecular imaging in dementia: Past, present, and future. <i>Alzheimer's and Dementia</i> , 2018, 14, 1522-1552.	0.4	68

#	ARTICLE	IF	CITATIONS
343	The development and validation of tau PET tracers: current status and future directions. <i>Clinical and Translational Imaging</i> , 2018, 6, 305-316.	1.1	135
344	Cognitive Impairment and Dementias. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 498-512.	2.5	7
345	Cysteine-Independent Inhibition of Alzheimer's Disease-like Paired Helical Filament Assembly by Leuco-Methylthioninium (LMT). <i>Journal of Molecular Biology</i> , 2018, 430, 4119-4131.	2.0	26
346	SPECT and PET imaging in Alzheimer's disease. <i>Annals of Nuclear Medicine</i> , 2018, 32, 583-593.	1.2	106
347	¹⁸ F-Labelled catecholamine type radiopharmaceuticals in the diagnosis of neurodegenerative diseases and neuroendocrine tumours: approaches to synthesis and development prospects. <i>Russian Chemical Reviews</i> , 2018, 87, 350-373.	2.5	12
348	Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study. <i>Neurobiology of Disease</i> , 2018, 117, 211-216.	2.1	46
349	Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with ¹⁸ F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles. <i>Journal of Nuclear Medicine</i> , 2019, 60, 107-114.	2.8	92
350	Sex modulates the ApoE μ 4 effect on brain tau deposition measured by ¹⁸ F-AV-1451 PET in individuals with mild cognitive impairment. <i>Theranostics</i> , 2019, 9, 4959-4970.	4.6	50
351	Quantitative ¹⁸ F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients. <i>Frontiers in Neurology</i> , 2019, 10, 486.	1.1	33
352	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging's Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , 2019, 76, 1174.	4.5	182
353	Tau Aggregation Correlates with Amyloid Deposition in Both Mild Cognitive Impairment and Alzheimer's Disease Subjects. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 455-465.	1.2	6
354	An one-pot two-step automated synthesis of [¹⁸ F]T807 injection, its biodistribution in mice and monkeys, and a preliminary study in humans. <i>PLoS ONE</i> , 2019, 14, e0217384.	1.1	3
355	Multi-modal latent factor exploration of atrophy, cognitive and tau heterogeneity in Alzheimer's disease. <i>NeuroImage</i> , 2019, 201, 116043.	2.1	38
356	[¹⁸ F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2077-2089.	3.3	84
357	Discovery and preclinical characterization of [¹⁸ F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2178-2189.	3.3	148
358	Multi-Modal Signatures of Tau Pathology, Neuronal Fiber Integrity, and Functional Connectivity in Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 3233-3243.	1.7	21
359	AD molecular: Imaging tau aggregates with positron emissions tomography. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 165, 107-138.	0.9	10
360	Cerebrospinal fluid amyloid levels are associated with delayed memory retention in cognitively normal biomarker-negative older adults. <i>Neurobiology of Aging</i> , 2019, 84, 90-97.	1.5	4

#	ARTICLE	IF	CITATIONS
361	The bivariate distribution of amyloid- β^2 and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , 2019, 142, 3230-3242.	3.7	129
362	[18F]-AV-1451 tau PET imaging in Alzheimer's disease and suspected non-AD tauopathies using a late acquisition time window. <i>Journal of Neurology</i> , 2019, 266, 3087-3097.	1.8	7
363	Cerebral Amyloid Angiopathy, Alzheimer's Disease and MicroRNA: miRNA as Diagnostic Biomarkers and Potential Therapeutic Targets. <i>NeuroMolecular Medicine</i> , 2019, 21, 369-390.	1.8	18
364	Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 757-768.	1.2	32
365	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2316.	3.8	223
366	Four-repeat tauopathies. <i>Progress in Neurobiology</i> , 2019, 180, 101644.	2.8	141
367	Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 45.	2.0	57
368	Gut Microbiota Alteration and Its Time Course in a Tauopathy Mouse Model. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 399-412.	1.2	37
369	Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site. <i>Annals of Nuclear Medicine</i> , 2019, 33, 375-382.	1.2	16
370	Effect of Off-Target Binding on ^{18}F -Flortaucipir Variability in Healthy Controls Across the Life Span. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1444-1451.	2.8	96
371	Radiosynthesis of a carbon-11-labeled AMPAR allosteric modulator as a new PET radioligand candidate for imaging of Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1177-1181.	1.0	4
372	Tau positron emission tomography imaging in C9orf72 repeat expansion carriers. <i>European Journal of Neurology</i> , 2019, 26, 1235-1239.	1.7	3
373	Discovery of <i>N</i> -(4- ^{18}F Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a New Promising Tau Positron Emission Tomography Imaging Tracer. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2974-2987.	2.9	24
374	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. <i>Brain</i> , 2019, 142, 1063-1076.	3.7	122
375	Dementia spectrum disorders: lessons learnt from decades with PET research. <i>Journal of Neural Transmission</i> , 2019, 126, 233-251.	1.4	32
376	Fact, Fiction, or Evolution: Mechanism Hypothesis of Alzheimer's Disease. , 2019, , .		0
377	Neuroimaging in aging and neurologic diseases. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 191-227.	1.0	25
378	Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. <i>Nature Medicine</i> , 2019, 25, 1680-1683.	15.2	328

#	ARTICLE	IF	CITATIONS
379	Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience. <i>Frontiers in Medicine</i> , 2019, 6, 268.	1.2	11
380	MRI Outperforms [18F]AV1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2019, 34, 105-113.	2.2	33
381	Positron emission tomography of tau in Iraq and Afghanistan Veterans with blast neurotrauma. <i>NeuroImage: Clinical</i> , 2019, 21, 101651.	1.4	33
382	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1152-1163.	3.3	30
383	Tau PET imaging in neurodegenerative tauopathies—still a challenge. <i>Molecular Psychiatry</i> , 2019, 24, 1112-1134.	4.1	409
384	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 638-651.	1.9	27
385	Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome. <i>Developmental Neurobiology</i> , 2019, 79, 711-715.	1.5	15
386	Biomarkers for tau pathology. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 18-33.	1.0	163
387	PET imaging of tau protein targets: a methodology perspective. <i>Brain Imaging and Behavior</i> , 2019, 13, 333-344.	1.1	43
388	Parametric methods for [¹⁸ F]flortaucipir PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 365-373.	2.4	22
389	Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 451-489.	3.3	86
390	Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies. <i>Biological Psychiatry</i> , 2020, 87, 808-818.	0.7	50
391	Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 342-354.	3.3	61
392	18F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2020, 267, 341-349.	1.8	21
393	Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	353
394	Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1949-1960.	3.3	11
395	Biological applications of near infrared fluorescence dye probes in monitoring Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2020, 187, 111982.	2.6	39
396	Tau-positron emission tomography correlates with neuropathology findings. <i>Alzheimer's and Dementia</i> , 2020, 16, 561-571.	0.4	113

#	ARTICLE	IF	CITATIONS
397	The Imaging Features and Clinical Associations of a Novel Tau PET Tracer ¹⁸ F-APN1607 in Alzheimer Disease. <i>Clinical Nuclear Medicine</i> , 2020, 45, 747-756.	0.7	20
398	¹⁸ F-MK-6240 PET for early and late detection of neurofibrillary tangles. <i>Brain</i> , 2020, 143, 2818-2830.	3.7	147
399	Relationship of amyloid beta and neurofibrillary tau deposition in Neurodegeneration in Aging Down Syndrome (NiAD) study at baseline. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12096.	1.8	15
400	Molecular Imaging of Fluorinated Probes for Tau Protein and Amyloid- β^2 Detection. <i>Molecules</i> , 2020, 25, 3413.	1.7	12
401	Coevolution of Atomic Resolution and Whole-Brain Imaging for Tau Neurofibrillary Tangles. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2513-2522.	1.7	8
402	Practical Synthesis of a Stable Precursor for Positron Emission Tomography Imaging Agent ¹⁸ F-GTP1. <i>Organic Process Research and Development</i> , 2020, 24, 1690-1699.	1.3	2
403	Compensating for choroid plexus based off-target signal in the hippocampus using ¹⁸ F-flortaucipir PET. <i>NeuroImage</i> , 2020, 221, 117193.	2.1	9
404	Iterative framework for image registration and partial volume correction in brain positron emission tomography. <i>Radiological Physics and Technology</i> , 2020, 13, 348-357.	1.0	4
405	Association of amyloid- β^2 CSF/PET discordance and tau load 5 years later. <i>Neurology</i> , 2020, 95, e2648-e2657.	1.5	33
406	Identification of a nanomolar affinity β -synuclein fibril imaging probe by ultra-high throughput <i>in silico</i> screening. <i>Chemical Science</i> , 2020, 11, 12746-12754.	3.7	30
407	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's <i>continuum</i> when only subtle changes in A β^2 pathology are detected. <i>EMBO Molecular Medicine</i> , 2020, 12, e12921.	3.3	202
408	A Study on PHF-Tau Network Effected by Apolipoprotein E4. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2020, 35, 153331752097141.	0.9	4
409	¹⁸ F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. <i>Brain</i> , 2020, 143, 3477-3494.	3.7	100
410	Positron Emission Tomography Imaging With [¹⁸ F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. <i>JAMA Neurology</i> , 2020, 77, 829.	4.5	244
411	Clinical evaluation of [¹⁸ F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3176-3185.	3.3	17
412	Progress in Analysis of Tau Protein. <i>Chinese Journal of Analytical Chemistry</i> , 2020, 48, 685-694.	0.9	5
413	Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum. <i>Brain</i> , 2020, 143, 1010-1026.	3.7	68
414	Functional Brain Network Connectivity Patterns Associated With Normal Cognition at Old-Age, Local β^2 -amyloid, Tau, and APOE4. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 46.	1.7	21

#	ARTICLE	IF	CITATIONS
415	T807-modified human serum albumin biomimetic nanoparticles for targeted drug delivery across the blood-brain barrier. <i>Journal of Drug Targeting</i> , 2020, 28, 1085-1095.	2.1	5
416	PET Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape. <i>Molecules</i> , 2020, 25, 977.	1.7	68
417	PET and SPECT imaging of the brain: a review on the current status of nuclear medicine in Japan. <i>Japanese Journal of Radiology</i> , 2020, 38, 343-357.	1.0	10
418	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. <i>NeuroImage: Clinical</i> , 2020, 25, 102152.	1.4	46
419	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 87, 556-567.	2.8	17
420	Molecular Tools to Detect Alloforms of A β and Tau: Implications for Multiplexing and Multimodal Diagnosis of Alzheimer's Disease. <i>Bulletin of the Chemical Society of Japan</i> , 2020, 93, 507-546.	2.0	39
421	Frontal variant of Alzheimer's disease with asymmetric presentation mimicking frontotemporal dementia: Case report and literature review. <i>Brain and Behavior</i> , 2020, 10, e01548.	1.0	18
422	Imaging biomarkers in neurodegeneration: current and future practices. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 49.	3.0	96
423	Neuronal mitochondria-targeted delivery of curcumin by biomimetic engineered nanosystems in Alzheimer's disease mice. <i>Acta Biomaterialia</i> , 2020, 108, 285-299.	4.1	77
424	Interaction effect of Alzheimer's disease pathology and education, occupation, and socioeconomic status as a proxy for cognitive reserve on cognitive performance: <i>in vivo</i> positron emission tomography study. <i>Psychogeriatrics</i> , 2020, 20, 585-593.	0.6	14
425	Regional [¹⁸ F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2866-2878.	3.3	29
426	Characterization of ¹⁸ F-PM-PBB3 (¹⁸ F-APN-1607) Uptake in the rTg4510 Mouse Model of Tauopathy. <i>Molecules</i> , 2020, 25, 1750.	1.7	26
427	Tau PET imaging with ¹⁸ F-PI-2620 in aging and neurodegenerative diseases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2233-2244.	3.3	37
428	The therapeutic potential of PROTACs. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 1-24.	2.4	29
429	Radiosynthesis and quality control testing of the tau imaging positron emission tomography tracer [¹⁸ F]PM-PBB3 for clinical applications. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2021, 64, 109-119.	0.5	14
430	Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid- β -negative cognitively normal individuals. <i>Neurobiology of Aging</i> , 2021, 97, 41-48.	1.5	23
431	Coordination chemistry of ligands: Insights into the design of amyloid beta/tau-PET imaging probes and nanoparticles-based therapies for Alzheimer's disease. <i>Coordination Chemistry Reviews</i> , 2021, 430, 213659.	9.5	8
432	Imaging of Tau Pathology in Neurodegenerative Diseases: An Update. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 253-263.	2.5	29

#	ARTICLE	IF	CITATIONS
433	Attenuation correction using deep Learning and integrated UTE/multi-echo Dixon sequence: evaluation in amyloid and tau PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1351-1361.	3.3	14
434	Synthesis and Evaluation of Fluorine-18 Labeled 2-Phenylquinoxaline Derivatives as Potential Tau Imaging Agents. <i>Molecular Pharmaceutics</i> , 2021, 18, 1176-1195.	2.3	16
435	Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1696.	3.3	3
436	Financial decision-making and capacity in older adults. , 2021, , 193-214.		0
437	Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies. <i>Molecular Imaging and Biology</i> , 2021, 23, 604-613.	1.3	10
438	Tauvidâ„¢: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimerâ€™s Disease. <i>Pharmaceuticals</i> , 2021, 14, 110.	1.7	56
440	Tau ^{IQ} : A Canonical Image Based Algorithm to Quantify Tau PET Scans. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1292-1300.	2.8	13
441	Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimerâ€™s disease and supporting differential diagnosis. <i>Annals of Nuclear Medicine</i> , 2021, 35, 139-147.	1.2	3
442	Development of molecular tools for diagnosis of Alzheimerâ€™s disease that are based on detection of amyloidogenic proteins. <i>Prion</i> , 2021, 15, 56-69.	0.9	12
443	Significant effects of cholinesterase inhibitors on tau pathology in the Alzheimer's disease continuum: An in vivo positron emission tomography study. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1274-1283.	1.3	5
444	Comprehensive review on design perspective of PET ligands based on Î²-amyloids, tau and neuroinflammation for diagnostic intervention of Alzheimerâ€™s disease. <i>Clinical and Translational Imaging</i> , 2021, 9, 153-175.	1.1	3
445	Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2200-2211.	3.3	19
446	Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimerâ€™s disease in the context of a structured 5-phase biomarker development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2097-2109.	3.3	34
447	Imaging Techniques in Alzheimerâ€™s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2110.	1.8	79
448	Cryo-EM structures of tau filaments from Alzheimerâ€™s disease with PET ligand APN-1607. <i>Acta Neuropathologica</i> , 2021, 141, 697-708.	3.9	99
449	Molecular Imaging Approaches in Dementia. <i>Radiology</i> , 2021, 298, 517-530.	3.6	27
450	Precision health in Alzheimer disease: Risk assessmentâ€¢based strategies. <i>Precision Medical Sciences</i> , 2021, 10, 54-70.	0.1	1
451	Alzheimerâ€™s Dementia: The Emerging Role of Positron Emission Tomography. <i>Neuroscientist</i> , 2022, 28, 507-519.	2.6	8

#	ARTICLE	IF	CITATIONS
452	Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research. <i>Alzheimer's and Dementia</i> , 2021, 17, 1554-1574.	0.4	114
453	Recent advances in pre-clinical diagnosis of Alzheimer's disease. <i>Metabolic Brain Disease</i> , 2021, , 1.	1.4	3
454	Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1091-1104.	1.2	17
455	Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 445.	4.5	33
456	Direct Comparison of the Tau PET Tracers ¹⁸ F-Flortaucipir and ¹⁸ F-MK-6240 in Human Subjects. <i>Journal of Nuclear Medicine</i> , 2022, 63, 108-116.	2.8	39
457	Molecular Imaging of Extrapyraxidal Movement Disorders With Dementia: The 4R Tauopathies. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 275-285.	2.5	3
458	The Effects of Amyloid and Tau on Functional Network Connectivity in Older Populations. <i>Brain Connectivity</i> , 2021, 11, 599-612.	0.8	7
459	Graph Models of Pathology Spread in Alzheimer's Disease: An Alternative to Conventional Graph Theoretic Analysis. <i>Brain Connectivity</i> , 2021, 11, 799-814.	0.8	9
460	Network interdigitations of Tau and amyloid β deposits define cognitive levels in aging. <i>Human Brain Mapping</i> , 2021, 42, 2990-3004.	1.9	7
461	PET Agents in Dementia: An Overview. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 196-229.	2.5	23
462	Turn-On Quinoline-Based Fluorescent Probe for Selective Imaging of Tau Aggregates in Alzheimer's Disease: Rational Design, Synthesis, and Molecular Docking. <i>ACS Sensors</i> , 2021, 6, 2281-2289.	4.0	28
463	[¹⁸ F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers. <i>Neurology</i> , 2021, 97, e1017-e1030.	1.5	16
464	ELISA Evaluation of Tau Accumulation in the Brains of Patients with Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 652-662.	0.9	4
465	Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 541-560.	1.2	18
466	Evaluation of [¹⁸ F]-JNJ-64326067-AAA tau PET tracer in humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 3302-3313.	2.4	15
467	Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , 2021, 17, 580-589.	4.9	144
469	Dynamic nanoassemblies for imaging and therapy of neurological disorders. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113832.	6.6	15
470	Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 103-117.	1.2	4

#	ARTICLE	IF	CITATIONS
471	Illuminating Protein Phase Separation: Reviewing Aggregation-Induced Emission, Fluorescent Molecular Rotor and Solvatochromic Fluorophore Based Probes. Chemistry - A European Journal, 2021, 27, 14564-14576.	1.7	12
472	Distinct amyloid and tau PET signatures are associated with diverging clinical and imaging trajectories in patients with amnesic syndrome of the hippocampal type. Translational Psychiatry, 2021, 11, 498.	2.4	8
473	Relationships between β -amyloid and tau in an elderly population: An accelerated failure time model. NeuroImage, 2021, 242, 118440.	2.1	15
474	PET imaging in Down syndrome and Alzheimer's disease. , 2022, , 173-192.		1
475	Sex differences in off-target binding using tau positron emission tomography. NeuroImage: Clinical, 2021, 31, 102708.	1.4	21
476	Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography. Methods in Molecular Biology, 2018, 1750, 221-229.	0.4	1
477	PET Neuroimaging in Dementia Conditions. , 2021, , 211-282.		7
478	PET Tracers for Beta-Amyloid and Other Proteinopathies. , 2014, , 199-212.		2
479	Myotonic Dystrophy: an RNA Toxic Gain of Function Tauopathy?. Advances in Experimental Medicine and Biology, 2019, 1184, 207-216.	0.8	10
480	Tau PET Imaging. Advances in Experimental Medicine and Biology, 2019, 1184, 217-230.	0.8	9
481	Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. NeuroImage, 2017, 157, 448-463.	2.1	341
482	New advances in tau imaging in parkinsonism. International Review of Psychiatry, 2017, 29, 628-635.	1.4	7
483	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain, 2020, 143, 3805-3815.	3.7	65
485	Multimodality Review of Amyloid-related Diseases of the Central Nervous System. Radiographics, 2016, 36, 1147-1163.	1.4	78
486	Chronic Traumatic Encephalopathy. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 187-207.	0.4	7
487	THE ROAD AHEAD TO CURE ALZHEIMER'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS. Journal of prevention of Alzheimer's disease, The, 2014, 1, 1-22.	1.5	48
488	Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms. Journal of Movement Disorders, 2018, 11, 1-12.	0.7	9
489	Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging. Current Medicinal Chemistry, 2016, 23, 1818-1869.	1.2	149

#	ARTICLE	IF	CITATIONS
490	Ligand and Structure-based Virtual Screening of Lamiaceae Diterpenes with Potential Activity against a Novel Coronavirus (2019-nCoV). <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 2126-2145.	1.0	12
491	First Tau PET Tracer Approved: Toward Accurate In Vivo Diagnosis of Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1409-1410.	2.8	20
492	Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 249-260.	1.2	50
493	Tau PET Imaging with [18F]PM-PBB3 in Frontotemporal Dementia with MAPT Mutation. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 149-157.	1.2	24
494	Pick's Tau Fibril Shows Multiple Distinct PET Probe Binding Sites: Insights from Computational Modelling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 349.	1.8	11
495	Alzheimer's disease: Unique markers for diagnosis & new treatment modalities. <i>Indian Journal of Medical Research</i> , 2015, 142, 369.	0.4	13
496	Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. <i>ELife</i> , 2019, 8, .	2.8	184
497	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2022, 18, 1370-1382.	0.4	17
499	Tau PET in Neurodegenerative Diseases Manifesting Dementia. , 2017, , 199-210.		0
500	Biomarkers of Alzheimer's Disease. <i>Mental Health and Illness Worldwide</i> , 2017, , 1-35.	0.1	0
501	Biomarkers of Alzheimer's Disease. <i>Mental Health and Illness Worldwide</i> , 2017, , 105-139.	0.1	0
502	Imaging in Neurology Research III: Neurodegenerative Diseases. , 2017, , 761-772.		0
504	Tau Imaging in Preclinical Alzheimer's Disease. <i>Neuromethods</i> , 2018, , 189-197.	0.2	0
508	Neuroimaging in Psychiatric Drug Development and Radioligand Development for New Targets. , 2021, , 3-15.		0
510	18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome. <i>Brain</i> , 2021, 144, 266-277.	3.7	7
511	High-yield synthesis of a tau PET radioligand and its nonradioactive ligand using an alternative protection and deprotection strategy. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2021, 64, 150-158.	0.5	2
512	Cerebral hypometabolism and grey matter density in MAPT intron 10 +3 mutation carriers. <i>American Journal of Neurodegenerative Disease</i> , 2014, 3, 103-14.	0.1	12
514	Taming Alzheimer's disease: New perspectives, newer horizons. <i>Iranian Journal of Neurology</i> , 2017, 16, 146-155.	0.5	4

#	ARTICLE	IF	CITATIONS
515	Automated production of [F]Flortaucipir for PET imaging of tauopathies. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 167-177.	1.0	2
516	Neuronal PET tracers for Alzheimer's disease. Biochemical and Biophysical Research Communications, 2022, 587, 58-62.	1.0	8
517	Tau Imaging in Neurodegenerative Dementia. , 2022, , 111-120.		0
518	¹⁸ F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies. Frontiers in Aging Neuroscience, 2021, 13, 761010.	1.7	16
519	Quâ€™apporte lâ€™imagerie hybride TEP-IRM dans lâ€™tude des pathologies neuro-dÃ©nÃ©ratives? Bulletin De L'Academie Nationale De Medecine, 2021, 206, 28-28.	0.0	0
520	Aluminium co-localises with Biondi ring tangles in Parkinsonâ€™s disease and epilepsy. Scientific Reports, 2022, 12, 1465.	1.6	3
521	Advances in Deep Neuropathological Phenotyping of Alzheimer Disease: Past, Present, and Future. Journal of Neuropathology and Experimental Neurology, 2022, 81, 2-15.	0.9	26
522	PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery, 2022, 21, 181-200.	21.5	912
523	¹ H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. Neurobiology of Aging, 2022, 112, 16-26.	1.5	9
524	Deep residual inception encoderâ€¦decoder network for amyloid PET harmonization. Alzheimer's and Dementia, 2022, 18, 2448-2457.	0.4	10
525	Lack of association between bridging integrator 1 (<i>BIN1</i>) rs744373 polymorphism and tauâ€¦PET load in cognitively intact older adults. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12227.	1.8	1
526	Increased retention of tau PET ligand [18F]-AV1451 in Alzheimerâ€™s Disease Psychosis. Translational Psychiatry, 2022, 12, 82.	2.4	6
527	Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 459-467.	0.9	19
529	Overview of tau PET molecular imaging. Current Opinion in Neurology, 2022, 35, 230-239.	1.8	18
530	Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy. Frontiers in Cellular Neuroscience, 2022, 16, 801179.	1.8	14
531	The Role of Tau beyond Alzheimerâ€™s Disease: A Narrative Review. Biomedicines, 2022, 10, 760.	1.4	12
532	Multicenter ¹⁸ F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimerâ€™s Disease. Biomolecules, 2022, 12, 458.	1.8	9
533	Recent development in selective Tau tracers for PET imaging in the brain. Chinese Chemical Letters, 2022, 33, 3339-3348.	4.8	5

#	ARTICLE	IF	CITATIONS
534	Tracer development for PET imaging of proteinopathies. <i>Nuclear Medicine and Biology</i> , 2022, 114-115, 115-127.	0.3	4
535	Tau and Alzheimer's Disease: Molecular Mechanisms and Treatment Approaches. <i>SN Comprehensive Clinical Medicine</i> , 2021, 4, 1.	0.3	0
536	Alzheimer's Disease: A Silent Pandemic – A Systematic Review on the Situation and Patent Landscape of the Diagnosis. <i>Recent Patents on Biotechnology</i> , 2022, 16, .	0.4	0
544	The tauopathies: Neuroimaging characteristics and emerging experimental therapies. <i>Journal of Neuroimaging</i> , 2022, 32, 565-581.	1.0	2
545	Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5023.	1.8	64
546	Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 838034.	1.7	19
547	PET Imaging in Preclinical Anti- $A\beta$ Drug Development. <i>Pharmaceutical Research</i> , 2022, 39, 1481-1496.	1.7	7
548	PET Imaging of Dementia. <i>Clinical Nuclear Medicine</i> , 2022, 47, 763-773.	0.7	7
550	Monoamine oxidase binding not expected to significantly affect [^{18}F]flortaucipir PET interpretation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3797-3808.	3.3	6
551	Tau PET Imaging in Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2022, 63, 20S-26S.	2.8	26
552	Impact of spill-in counts from off-target regions on [^{18}F]Flortaucipir PET quantification. <i>NeuroImage</i> , 2022, 259, 119396.	2.1	3
553	Positron Emission Tomography-Based Assessment of Cognitive Impairment and Dementias, Critical Role of Fluorodeoxyglucose in such Settings. <i>PET Clinics</i> , 2022, 17, 479-494.	1.5	3
554	Molecular Simulations Reveal Distinct Energetic and Kinetic Binding Properties of [^{18}F]PI-2620 on Tau Filaments from 3R/4R and 4R Tauopathies. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2222-2234.	1.7	10
555	Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease. <i>Brain</i> , 2022, 145, 4489-4505.	3.7	23
556	DeepPVC: prediction of a partial volume-corrected map for brain positron emission tomography studies via a deep convolutional neural network. <i>EJNMMI Physics</i> , 2022, 9, .	1.3	3
558	Investigating Tau and Amyloid Tracer Skull Binding in Studies of Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2023, 64, 287-293.	2.8	8
560	Longitudinal Tau PET Using ^{18}F -Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters. <i>Journal of Nuclear Medicine</i> , 2023, 64, 281-286.	2.8	2
561	Molecular imaging evidence in favor or against PDD and DLB overlap. , 2023, , 275-295.		1

#	ARTICLE	IF	CITATIONS
562	PET molecular imaging for pathophysiological visualization in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 765-783.	3.3	18
563	Discovery and evaluation of aza-fused tricyclic derivatives for detection of Tau pathology in Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2023, 246, 114991.	2.6	4
565	Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging. <i>Insights Into Imaging</i> , 2023, 14, .	1.6	5
566	Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study. <i>ELife</i> , 0, 12, .	2.8	15
567	<i>Dementia and Mild Neurocognitive Disorders.</i> , 2022, , .		0
568	Individualized network analysis: A novel approach to investigate tau PET using graph theory in the Alzheimer's disease continuum. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	2
569	The Sensitivity of Tau Tracers for the Discrimination of Alzheimer's Disease Patients and Healthy Controls by PET. <i>Biomolecules</i> , 2023, 13, 290.	1.8	11
570	Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer's Disease. <i>Cellular and Molecular Neurobiology</i> , 2023, 43, 2491-2523.	1.7	8
571	Determinants of physical activity engagement in older adults. <i>Journal of Behavioral Medicine</i> , 2023, 46, 757-769.	1.1	0
572	Progressive Supranuclear Palsy in 2022: recent developments and an eye to the future. <i>Advances in Clinical Neuroscience & Rehabilitation: ACNR</i> , 0, , .	0.1	0
573	Dumbbell Aptamer Sensor Based on Dual Biomarkers for Early Detection of Alzheimer's Disease. <i>ACS Applied Materials & Interfaces</i> , 2023, 15, 16394-16407.	4.0	2
575	Tau positron emission tomography in tauopathies: A narrative review. <i>Precision and Future Medicine</i> , 2023, 7, 7-24.	0.5	0
577	Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment. <i>Journal of Alzheimer's Disease</i> , 2023, 93, 765-777.	1.2	2
581	Functional MRI Studies of Memory in Aging, Mild Cognitive Impairment, and Alzheimer's Disease. , 2023, , 671-712.		0
586	Traits and Trammels of Tau Tracer Imaging. , 2023, , 85-107.		0
587	What Is Neurodegeneration?. , 2023, , 1-13.		0
592	Neuroimaging Biomarkers in Alzheimer's Disease and Related Disorders. , 2023, , 163-188.		0
593	A closer look at amyloid ligands, and what they tell us about protein aggregates. <i>Chemical Society Reviews</i> , 2024, 53, 1354-1374.	18.7	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------